NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Tolerance Bio, Inc.

Tolerance Bio, Inc.

Private
Philadelphia, PennsylvaniaHealthcare & Life Scienceshttps://tolerancebio.com

Last Round

Early Stage

VC

Jun 18, 2026

Total Funding Raised

$20.2M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Tolerance Bio, Inc. is a biopharmaceutical company developing therapies focused on manipulating immune tolerance via the thymus to address various immune-mediated diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B2C

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

allogeneic cell therapyiPSCinduced pluripotent stem celloff the shelf cell therapythymic organoidsthymus restorationartificial thymusimmune restorationregenerative medicinecell therapy platformimmune tolerancelongevity biotechhealthspan extensionautoimmunityDiGeorge syndromeRNA delivery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Tolerance Bio, Inc. Comparables

Compare Tolerance Bio, Inc. with similar companies based on industry and business-model similarity.

Tolerance Bio, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Thymmune Therapeutics
90%
TECregen
76%
Sumitomo Pharma Co., Ltd.
73%

Tolerance Bio, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early Stage VCJun 18, 2026
SeedDec 19, 2024

Key People

Founding team and executive leadership

Francisco Leon

Founder, CEO

Founding Team

Justin Vogel

Founding Team Member, CFO, Director

Founding Team

Tolerance Bio, Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    $15.1M raised in an early stage VC round.

Tolerance Bio, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Tolerance Bio, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Tolerance Bio, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersPhiladelphia, Pennsylvania
Employee Range16
Year Founded2023
Last FundingJun 18, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.